<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150447</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS09420</org_study_id>
    <secondary_id>0910090</secondary_id>
    <secondary_id>1210520</secondary_id>
    <nct_id>NCT02150447</nct_id>
  </id_info>
  <brief_title>The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding</brief_title>
  <official_title>Effect of Proton Pump Inhibitor on Prevention of Tumor Bleeding in Patients Under Palliative Chemotherapy for Unresectable Gastric Cancer: a Randomized, Double Blind, and Placebo Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the effect of proton pump inhibitor (PPI) with respect to gastric&#xD;
      cancer bleeding in inoperable patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumor bleeding frequently occurs in inoperable gastric cancer patients. Inoperable gastric&#xD;
      cancer usually has a large ulcer with friable tumor vessels. Acidic environment in stomach&#xD;
      prevents adequate function of coagulation cascade and decrease clot stability. Gastric cancer&#xD;
      bleeding may cause significant morbidity and often delays scheduled chemotherapy. National&#xD;
      Center Center data showed that about 30% of gastric cancer patient undergoing palliative&#xD;
      chemotherapy eventually experience significant cancer bleeding during the treatment period.&#xD;
      Once bleeding occurs, endoscopic management is more difficult in gastric cancer patients than&#xD;
      in patients with benign peptic ulcers, because the malignant ulcer bed has significant&#xD;
      fibrosis. Consequently, gastric cancer patient has a high risk of rebleeding.&#xD;
&#xD;
      Proton pump inhibitor (PPI, lansoprazole for example) decrease gastric acid secretion by&#xD;
      inhibiting H+,K+-ATPase, and subsequently stabilize blood clot. PPIs are commonly used for&#xD;
      benign peptic ulcer or reflux esophagitis, and PPI can decrease recurrent benign ulcer&#xD;
      bleeding or other ulcer complications. Moreover, it was reported to prevent bleeding from&#xD;
      NSAID or aspirin induced gastric ulcer. Because PPIs are very safe, and they are even&#xD;
      available as over-the-counter drugs in some countries. Furthermore, the drug has no&#xD;
      interaction with major chemotherapeutic agents commonly used for gastric cancer. Moreover,&#xD;
      the drugs are prescribed to the gastric cancer patients when tumor bleeding occurs. Although&#xD;
      gastric cancer bleeding is not uncommon and clinically challenging problem, there has been no&#xD;
      recommended measure to prevent cancer bleeding. Also there has been no report about the&#xD;
      efficacy of PPIs on the gastric cancer bleeding prevention up to now.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enroll rate&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-bleeding event</measure>
    <time_frame>Up to 6 years of study period</time_frame>
    <description>Evaluation of the effect of PPI on the prevention of gastric cancer bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion requirement (packed RBC unit)</measure>
    <time_frame>Up to 6 years of study period</time_frame>
    <description>Unit of packed RBC required at the time of tumor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of endoscopy to evaluate tumor bleeding</measure>
    <time_frame>Up to 6 years of study period</time_frame>
    <description>No of endoscopic session to evaluation bleeding from advanced gastric cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of endoscopic treatment for cancer bleeding</measure>
    <time_frame>Up to 6 years of study period</time_frame>
    <description>Total number of endoscopic treatment perfomed for gastric cancer bleeding in each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 6 years of study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for the prevention of gastric cancer bleeding</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton pump inhibitor</intervention_name>
    <description>Lansoprazole 30 mg, daily</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Lansoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, daily</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven primary gastric adenocarcinoma&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Plan for 1st line or 2nd line palliative chemotherapy&#xD;
&#xD;
          -  Cancer staging: metastatic (TxNxM1) or locally advanced unresectable gastric cancer&#xD;
             (T4NxMx with unresectable), or T2-3NxMx with inoperable condition&#xD;
&#xD;
          -  Performance status (PS) of 0 to 2 on Eastern Cooperative Oncology Group (ECOG) scale&#xD;
&#xD;
          -  Adequate organ functions defined as indicated below: (a) WBC &gt; 3000/mm3, (b) Hb 9.0&#xD;
             g/dL regardless of any transfusion history, (c) Platelet ≥100,000/mm3, (d) AST/ALT ≤&#xD;
             2.5 x UNL (≤ 5 x UNL if liver metastases are present) (e) Total bilirubin ≤1.5x UNL&#xD;
             (f) Cr ≤1.5 x UNL&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignancy within the past 3 years except adequately treated non-melanomatous&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Patients with significant or uncontrolled gastrointestinal bleeding in the past two&#xD;
             weeks without evidence of resolution documented by endoscopy or colonoscopy&#xD;
&#xD;
          -  Previous subtotal gastrectomy or total gastrectomy&#xD;
&#xD;
          -  Patient with a plan for neo-adjuvant chemotherapy&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome, or inability to take oral medication&#xD;
&#xD;
          -  Allergy history to proton pump inhibitor&#xD;
&#xD;
          -  Serious concurrent infection or nonmalignant illness that is uncontrolled or whose&#xD;
             control may be jeopardized by complications of study therapy&#xD;
&#xD;
          -  Inadequate cardiovascular function: (a) New York Heart Association class III or IV&#xD;
             heart disease, (b) Unstable angina or myocardial infarction within the past 6 months,&#xD;
             (c) History of significant ventricular arrhythmia requiring medication with&#xD;
             antiarrhythmics or significant conduction system abnormality&#xD;
&#xD;
          -  Requirement for therapeutic anticoagulant therapy, aspirin or non-steroidal&#xD;
             anti-inflammatory agents except COX-2 selective inhibitor&#xD;
&#xD;
          -  Requirement for therapeutic corticosteroid; the use of dexamethasone as anti-emetics&#xD;
             or a premedication of chemotherapy-associated hypersensitivity is not an exclusion&#xD;
             criteria&#xD;
&#xD;
          -  Need for PPI maintenance treatment for uncontrolled reflux esophagitis or active&#xD;
             peptic ulcer&#xD;
&#xD;
          -  Psychiatric disorder that would preclude compliance&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Untreated folate or vitamine B12 deficiency anemia&#xD;
&#xD;
          -  Bone marrow metastasis, or evidence of microangiopathic hemolytic anemia (MAHA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwang Ha Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moo In Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosin University Gospel Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Sup Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>620-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeong Sang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Il Ju Choi</investigator_full_name>
    <investigator_title>Head of Gastric Cancer Cencer</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer bleeding</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

